Journal Mobile Options
Table of Contents
Vol. 27, No. 4, 2009
Issue release date: November 2009
Dig Dis 2009;27:450–454

Therapeutic Options to Modulate Barrier Defects in Inflammatory Bowel Disease

Hering N.A. · Schulzke J.-D.
Department of General Medicine, Charité Center 10, Campus Benjamin Franklin, Berlin, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


In inflammatory bowel disease (IBD), epithelial barrier function is impaired contributing to diarrhea by a leak flux mechanism and perpetuating inflammation by an increased luminal antigen uptake. This barrier of the intestinal epithelium is composed of the apical enterocyte membrane and the epithelial tight junction (TJ) and can be affected by TJ alterations, induction of epithelial apoptoses and appearance of gross lesions like erosions or ulcers as well as by accelerated transcytotic antigen uptake. TJ strands are reduced in Crohn’s disease (CD) and strand breaks appear. Several of the 24 claudins are concerned in CD as e.g. claudin-2, -5 and -8. The epithelial apoptotic rate has also been shown to be elevated causing focal lesions. As far as regulation is concerned, Th1 cytokines like TNF-α and interferon-γ are important for CD, while Th2 responses are dominated by interleukin (IL)-13 and TNF-α in ulcerative colitis (UC). IL-13 does stimulate epithelial apoptosis as well as upregulates claudin-2 in UC. Together with an IL-13-dependent restitution arrest, this may explain why ulcer lesions are seen already early in UC but only in advanced stages of CD. Luminal antigen uptake occurs via TJ discontinuities, epithelial gross lesions and endocytotically. Therapeutically, anti-inflammatory remedies as e.g. TNF-α antibodies are most effective in improving active IBD and in parallel repairing barrier function. Again, this is assumed to be due to reduced cytokine release in active IBD, as a result of immune cell apoptosis. However, other agents can also directly affect barrier function. Glutamine is discussed as a candidate for barrier therapy but has never been shown to have a direct barrier influence in CD, although it is an important metabolic fuel for enterocytes and has been shown to preserve barrier functions in laboratory models. Also, probiotics and TGF-β and have beneficial effects in models, but no data exist on barrier repair in IBD. In contrast, zinc has been shown to improve barrier function in CD, although the inherent mechanisms are unknown. Finally, food components can strengthen the epithelial barrier as for example the flavonoid quercetin which has been shown to upregulate claudin-4 within the epithelial TJ.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Claude P: Morphological factors influencing transepithelial permeability: a model for the resistance of the zonula occludens. J Membr Biol 1978;39:219–232.
  2. Gitter AH, Wullstein F, Fromm M, Schulzke JD: Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001;121:1320–1328.
  3. Schurmann G, Bruwer M, Klotz A, Schmid KW, Senninger N, Zimmer KP: Transepithelial transport processes at the intestinal mucosa in inflammatory bowel disease. Int J Colorectal Dis 1999;14:41–46.
  4. Soderholm JD, Streutker C, Yang PC, Paterson C, Singh PK, McKay DM, Sherman PM, Croitoru K, Perdue MH: Increased epithelial uptake of protein antigens in the ileum of Crohn’s disease mediated by tumour necrosis factor-α. Gut 2004;53:1817–1824.
  5. Andre F, Andre C, Emery Y, Forichon J, Descos L, Minaire Y: Assessment of the lactulose-mannitol test in Crohn’s disease. Gut 1988;29:511–515.
  6. Adenis A, Colombel JF, Lecouffe P, Wallaert B, Hecquet B, Marchandise X, Cortot A: Increased pulmonary and intestinal perme-ability in Crohn’s disease. Gut 1992;33:678–682.
  7. Sanderson IR, Boulton P, Menzies I, Walker-Smith JA: Improvement of abnormal lac- tulose/rhamnose permeability in active Crohn’s disease of the small bowel by an elemental diet. Gut 1987;28:1073–1076.
  8. Zoli G, Care M, Parazza M, Spano C, Biagi PL, Bernardi M, Gasbarrini G: A randomized controlled study comparing elemental diet and steroid treatment in Crohn’s disease. Aliment Pharmacol Ther 1997;11:735–740.
  9. Zeissig S, Bojarski C, Buergel N, Mankertz J, Zeitz M, Fromm M, Schulzke JD: Downregulation of epithelial apoptosis and barrier repair in active Crohn’s disease by tumour necrosis factor-α antibody treatment. Gut 2004;53:1295–1302.
  10. Gennari R, Alexander JW: Arginine, glutamine, and dehydroepiandrosterone reverse the immunosuppressive effect of prednisone during gut-derived sepsis. Crit Care Med 1997;25:1207–1214.
  11. Li J, Langkamp-Henken B, Suzuki K, Stahlgren LH: Glutamine prevents parenteral nutrition-induced increases in intestinal permeability. JPEN J Parenter Enteral Nutr 1994;18:303–307.
  12. Akobeng AK, Miller V, Stanton J, Elbadri AM, Thomas AG: Double-blind randomized controlled trial of glutamine-enriched polymeric diet in the treatment of active Crohn’s disease. J Pediatr Gastroenterol Nutr 2000;30:78–84.
  13. Den Hond E, Hiele M, Peeters M, Ghoos Y, Rutgeerts P: Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn’s disease. JPEN J Parenter Enteral Nutr 1999;23:7–11.
  14. Czerucka D, Dahan S, Mograbi B, Rossi B, Rampal P: Saccharomyces boulardii preserves the barrier function and modulates the signal transduction pathway induced in enteropathogenic Escherichia coli-infected T84 cells. Infect Immun 2000;68:5998–6004.
  15. Madsen K, Cornish A, Soper P, McKaigney C, Jijon H, Yachimec C, Doyle J, Jewell L, De Simone C: Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001;121:580–591.
  16. Montalto M, Maggiano N, Ricci R, Curigliano V, Santoro L, Di Nicuolo F, Vecchio FM, Gasbarrini A, Gasbarrini G: Lactobacillus acidophilus protects tight junctions from aspirin damage in HT-29 cells. Digestion 2004;69:225–228.
  17. Planchon SM, Martins CA, Guerrant RL, Roche JK: Regulation of intestinal epithelial barrier function by TGF-β1. Evidence for its role in abrogating the effect of a T-cell cytokine. J Immunol 1994;153:5730–5739.
  18. McKaig BC, Makh SS, Hawkey CJ, Podolsky DK, Mahida YR: Normal human colonic subepithelial myofibroblasts enhance epithelial migration (restitution) via TGF-β3. Am J Physiol 1999;276:G1087–G1093.
  19. Howe KL, Reardon C, Wang A, Nazli A, McKay DM: Transforming growth factor-β regulation of epithelial tight junction proteins enhances barrier function and blocks enterohemorrhagic Escherichia coli O157:H7-induced increased permeability. Am J Pathol 2005;167:1587–1597.
  20. Sturniolo GC, Di Leo V, Ferronato A, D’Odorico A, D’Inca R: Zinc supplementation tightens ‘leaky gut’ in Crohn’s disease. Inflamm Bowel Dis 2001;7:94–98.
  21. Amasheh M, Schlichter S, Amasheh S, Mankertz J, Zeitz M, Fromm M, Schulzke JD: Quercetin enhances epithelial barrier function and increases claudin-4 expression in Caco-2 cells. J Nutr 2008;138:1067–1073.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50